Search Results
Your search for ,NhS matches 324 pages
Showing 1 - 50Effect of High-Risk Cytogenetic Abnormalities in Multiple Myeloma
In a retrospective study reported in the Journal of Clinical Oncology, Kaiser et al found that the presence of two or more high-risk cytogenetic abnormalities was associated with poorer outcomes in patients with newly diagnosed multiple myeloma (MM) and relapsed or refractory MM. Study Details The...
Masood Moghul, PhD, on a Mobile Prostate Cancer Clinical Unit: Findings From the Man Van
Masood Moghul, PhD, of The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, describes the impact of a nurse-led mobile clinical unit on targeted screening invitations to men at high risk for prostate cancer in disadvantaged communities in London (Abstract 317).
Pembrolizumab in Previously Treated Advanced Clear Cell Gynecological Cancers
As reported in JAMA Oncology by Kristeleit et al, the UK-based phase II PEACOCC trial has shown the benefit of pembrolizumab in previously treated patients with advanced clear cell gynecological cancers (CCGCs). As stated by the investigators, “Advanced CCGCs have a poor prognosis, with response...
Nicholas D. James, PhD, FRCP, MBBS, on an ADT Option: Transdermal Estradiol Patches
Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, discusses findings from an embedded phase II randomized study from the STAMPEDE trial. The study assessed the efficacy and toxicity of transdermal estradiol patches vs...
Mobile Prostate Cancer Screening Clinic Was Effective in Detecting Prostate Cancer in Underserved Men
Globally, prostate cancer is the second most frequently diagnosed cancer and the fifth-leading cause of cancer-related death among men—and the leading cause of cancer-related death in Central America and sub-Saharan Africa. Four years ago, British researchers launched the “Man Van” pilot mobile...
Novel Menin Inhibitors Show Safety and Activity in Several Clinical Trials
The recently approved menin inhibitor revumenib is poised to improve the treatment of acute myeloid leukemia (AML), specifically for disease with a KMT2A rearrangement. Promising results for other novel menin inhibitors now in development—with their unique safety and activity profiles—suggest the...
Risk of Second Primary Cancers After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers
In an English study reported in the Journal of Clinical Oncology, Allen et al found that patients with breast cancer harboring BRCA1/BRCA2 pathogenic variants were at high risk of second primary cancers. Study Details and Results The study involved follow-up of 25,811 females and 480 males...
Scientists Develop a ‘Digital Twin’ Model to Predict Cancer Treatment Responses
Researchers have created a “digital twin” model constructed from the clinical and molecular profiles of patients with cancer that accurately predicted how a patient is likely to respond to a specific chemotherapy. The approach optimizes the treatment choice for patients using available clinical...
Addition of Induction Chemotherapy to Standard Chemoradiotherapy in Locally Advanced Cervical Cancer
As reported in The Lancet by McCormack et al, the phase III INTERLACE trial has shown improved progression-free and overall survival with the addition of induction chemotherapy to standard chemoradiotherapy in patients with locally advanced cervical cancer. Study Details In the open-label trial,...
Neoadjuvant Pembrolizumab May Improve Outcomes in Some Patients With Colorectal Cancer Surgery
Researchers examined whether the PD-1 inhibitor pembrolizumab given neoadjuvantly may improve outcomes in certain patients with stage II or III mismatch repair–deficient/microsatellite instability–high colorectal cancer. Interim findings from the phase II NEOPRISM-CRC clinical trial were presented...
United Kingdom’s First Cardio-Oncology Service: 10-Year Experience
In a research letter published by Andres et al in JACC: CardioOncology, staff from Royal Brompton Hospital, Guy’s and St. Thomas’ NHS Foundation Trust in London described their experience over 10 years in the UK’s first cardio-oncology service. Study Details The study involved data from the initial ...
Neoadjuvant Chemoimmunotherapy in Patients With Early-Stage NSCLC
In a systematic review and meta-analysis reported in JAMA Network Open, Banna et al found that neoadjuvant chemoimmunotherapy was associated with improved event-free survival and pathologic complete response compared with neoadjuvant chemotherapy alone in patients with early-stage non–small cell...
Stage III Colorectal Cancer: Association of Immunoscore With Disease-Free Survival
In an analysis of two trials (SCOT and IDEA-HORG) reported in the Journal of Clinical Oncology, Domingo et al identified the predictive value of Immunoscore for disease-free survival in patients with stage III colorectal cancer treated with adjuvant mFOLFOX6 (modified fluorouracil, leucovorin, and...
Mary McCormack, PhD, MBBS, on Locally Advanced Cervical Cancer: Results From the INTERLACE Trial
Mary McCormack, PhD, MBBS, of University College London Hospitals, NHS Foundation Trust, discusses the global health issue of cervical cancer and a way forward. Phase III findings from the GCIG INTERLACE trial showed that induction chemotherapy with weekly paclitaxel and carboplatin before...
Expert Point of View: Lisa Pickering, PhD, FRCP
Invited discussant Lisa Pickering, PhD, FRCP, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, London, considered belzutifan to be a major advance in renal cell carcinoma (RCC). “LITESPARK-005 met both its primary endpoints of progression-free survival and overall response...
Final Results of the POUT Trial: Adjuvant Chemotherapy vs Surveillance After Nephroureterectomy for Upper Tract Urothelial Cancer
As reported in the Journal of Clinical Oncology by Alison Jane Birtle, MD, MBBS, MRCP, FRCR, and colleagues, final results of the UK-based phase III POUT trial showed survival benefits with adjuvant platinum-based chemotherapy vs surveillance after radical nephroureterectomy in patients with upper...
In NPM1-Mutated AML, Benefit of Transplant Limited to Patients With Residual Disease
In patients with NPM1-mutated acute myeloid leukemia (AML), the presence of molecular measurable residual disease (MRD) in the peripheral blood following induction chemotherapy can aid decision-making about postremission therapy. More specifically, MRD status in the peripheral blood can identify...
Intensified vs Standard Induction in Younger Patients With Newly Diagnosed AML
In a UK trial (NCRI AML19) reported in the Journal of Clinical Oncology, Russell et al found that intensified induction therapy with FLAG-Ida (fludarabine, cytarabine, granulocyte colony–stimulating factor, and idarubicin) plus gemtuzumab ozogamicin did not improve overall survival in younger...
Expert Point of View: Elizabeth Smyth, MD
Invited discussant of the phase I trial of the claudin 18.2-specific antibody-drug conjugate CMG901 in advanced gastric or gastroesophageal junction cancer was Elizabeth Smyth, MD, of Oxford University Hospitals NHS Foundation Trust. She said CMG901 demonstrated “encouraging results,” but more...
Presence of MRD After Chemotherapy May Predict Benefit From Donor Transplant in NPM1-Mutated AML
Among patients who have acute myeloid leukemia (AML) with genetic mutations in NPM1, those with no residual leukemia cells in the blood based on high-sensitivity testing after two cycles of chemotherapy achieved high rates of overall survival at 3 years and saw no additional survival benefit from...
Nicholas C. Turner, MD, PhD, on High-Risk Early-Stage Breast Cancer: Profiling Primary Tumors
Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Foundation Trust, and the Institute of Cancer Research, London, discusses the monarchE trial, which evaluated molecular profiling of archived primary tumor tissue from patients with hormone receptor–positive, HER2-negative,...
Abemaciclib Plus AI in Postmenopausal Patients With Advanced Breast Cancer: Final Overall Survival Analysis From MONARCH 3
Final overall survival results from the MONARCH 3 trial were reported in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (Abstract GS01-12). MONARCH 3 evaluated abemaciclib in combination with an aromatase inhibitor (AI) compared with an AI alone as initial...
Some Breast Cancer Survivors May Safely De-escalate Mammography 3 Years After Surgery
Women aged 50 or older who had less-frequent mammography 3 years after curative surgery for early-stage breast cancer had similar outcomes as women who had annual mammography, according to results from the Mammo-50 trial presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS03-02)....
Expert Point of View: Elizabeth Smyth, MD
Invited discussant, Elizabeth Smyth, MD, a consultant in gastrointestinal oncology at the Oxford University Hospitals NHS Foundation Trust in the United Kingdom, commented on the notable impact in pathologic complete response rates with the addition of checkpoint inhibitors in MATTERHORN and...
PACE Trials Support Stereotactic Body Radiotherapy for Some Patients With Localized Prostate Cancer
Prostate cancer treatment just got a major boost from the PACE trials, which may have established a new standard of care in low- and favorable intermediate-risk disease, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 The results of the phase ...
Update From monarchE: Benefit of Abemaciclib Increases Over Time in Early-Stage Breast Cancer
Results of a planned interim overall survival analysis of the phase III monarchE trial offered further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk disease, according to Stephen R.D....
Expert Point of View: Michail Ignatiadis, MD, PhD and Stephen R.D. Johnston, MD, PhD
The September 2023 European Society for Medical Oncology (ESMO) Virtual Plenary presentation of the NATALEE health-related quality-of-life (QOL) findings was discussed by Michail Ignatiadis, MD, PhD, and Stephen R.D. Johnston, MD, PhD. Dr. Ignatiadis is Director of the Breast Medical Oncology...
AI Software Demonstrates Potential to Accurately Detect Skin Cancer
A novel artificial intelligence (AI) software may be effective in detecting skin cancer and precancerous lesions, according to findings presented by Andrew et al at the European Academy of Dermatology and Venereology Congress 2023. Background Skin cancer detection using AI software has rapidly...
SBRT vs Standard Radiotherapy for Localized Prostate Cancer: 5-Year Analysis of PACE B
People with intermediate-risk, localized prostate cancer may be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggested. The findings, which...
Addition of Olaparib to Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Overall Survival Results in the PROpel Trial
As reported by Fred Saad, MD, and colleagues in The Lancet Oncology, the final prespecified overall survival analysis of the phase III PROpel trial showed no significant benefit with the addition of first-line olaparib to abiraterone in patients with metastatic castration-resistant prostate cancer...
Relapsed Pediatric T-Cell ALL: Base-Edited CAR7 T Cells
In an interim analysis of a small phase I study reported in The New England Journal of Medicine, Chiesa et al found that base-edited CAR7 T cells were active in pediatric patients with relapsed T-cell acute lymphoblastic leukemia (ALL). As stated by the investigators: “Cytidine deamination that is...
Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin
Nigel Russell, MD, of Guy’s and St. Thomas’ NHS Foundation Trust, discusses the latest results from the AML19 trial, which showed the chemotherapy regimen FLAG-Ida (fludarabine, high-dose cytarabine, idarubicin, and granulocyte-colony stimulating factor), when combined with gemtuzumab ozogamicin,...
Bladder-Sparing Trimodal Therapy vs Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer
In a retrospective study reported in the Journal of Clinical Oncology, Swinton et al found that bladder-sparing trimodal therapy with radical-dose radiotherapy was an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer. As stated by the ...
First-Line Atezolizumab vs Single-Agent Chemotherapy in Patients With Advanced NSCLC Ineligible for Platinum-Based Chemotherapy
In the phase III IPSOS trial reported in The Lancet, Lee et al found that first-line atezolizumab improved overall survival vs single-agent chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) who were ineligible for platinum-based chemotherapy. Study Details In the open-label...
Ruxolitinib for Patients With Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide
In a UK phase II trial (MAJIC-PV) reported in the Journal of Clinical Oncology, Harrison et al found that ruxolitinib produced a higher complete response rate vs best available therapy in patients with polycythemia vera intolerant of or resistant to hydroxycarbamide. Study Details In the...
Thomas Powles, MD, PhD, and Christopher Sweeney, MBBS, on RCC: Expert Review of Two Key Studies on Atezolizumab, Nivolumab, and Ipilimumab
Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss two important phase III studies on renal cell cancer (RCC) presented at ESMO 2022: IMmotion010, which examined the efficacy and safety of...
Addition of Vistusertib to Paclitaxel in Platinum-Resistant Ovarian High-Grade Serous Carcinoma
In the UK phase II OCTOPUS study reported in JAMA Oncology, Susana Banerjee, MBBS, MA, PhD, and colleagues found that the addition of the dual mTORC1/mTORC2 inhibitor vistusertib to weekly paclitaxel did not improve progression-free survival among patients with platinum-resistant or -refractory...
Elizabeth Smyth, MD, Offers Insight on KEYNOTE-859 Findings
The invited discussant of KEYNOTE-859,1 Elizabeth Smyth, MD, consultant in gastrointestinal oncology at Cambridge University Hospitals NHS Foundation Trust in the United Kingdom, called the findings “practice-changing” but cautioned that better patient selection is needed to optimally apply them....
When Can You Stop Lenalidomide Maintenance in Myeloma?
A study aimed at determining the optimal duration of lenalidomide maintenance after autologous stem cell transplantation for multiple myeloma has not answered that question, per se, but has yielded some hints that may inform future clinical trials. The follow-up analysis of the UK NCRI Myeloma XI...
Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Phase III Results on Cabozantinib, Nivolumab, and Ipilimumab
Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, discusses new data from the COSMIC-313 study of patients with advanced renal cell carcinoma of IMDC (International Metastatic RCC Database Consortium) intermediate or poor risk. Those who received cabozantinib...
KEYNOTE-859 Interim Analysis: Overall Survival Benefit for First-Line Pembrolizumab in Advanced Gastric Cancer
Results of the interim analysis of KEYNOTE-859 are in, and they confirm the overall survival benefit of first-line immunotherapy plus chemotherapy in advanced gastric cancer. Pembrolizumab plus a fluoropyrimidine- and platinum-containing doublet provided a statistically significant improvement in...
New Predictive Epidemiologic Model May Identify Individuals at High Risk for Endometrial Cancer
Investigators have developed a predictive model that may be used in research and eventually clinical settings to identify individuals at high risk of developing endometrial cancer who would benefit from screenings, according to a report published by Shi et al in the Journal of the National Cancer...
Subset of Patients With Advanced Gastric Cancer May Benefit From Claudin18.2-Targeted Agent Zolbetuximab
Initial data from the global phase III SPOTLIGHT trial may herald the use of a new targeted agent for a subset of patients with advanced gastric or gastroesophageal junction adenocarcinoma.1 The addition ofzolbetuximab, which targets the transmembrane protein claudin18.2 (CLDN18.2), to chemotherapy ...
Update From monarchE: Benefit of Abemaciclib Increases Over Time in Early-Stage Breast Cancer
Results of a planned interim overall survival analysis of the phase III monarchE trial offered further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk disease, according to Stephen R.D....
Endoscopic Surveillance With Systematic Random Biopsy vs Targeted Biopsy for Early Diagnosis of Hereditary Diffuse Gastric Cancer
In a UK study reported in The Lancet Oncology, Lee et al found that systematic random biopsies were more likely than endoscopically targeted biopsies to first detect signet ring cell carcinoma during endoscopic surveillance of individuals meeting testing criteria for hereditary diffuse gastric...
Updated Data From a Phase II Trial of Triplet Therapy in HPV-Positive Cancers
Expanded interim data from a phase II clinical trial investigating PDS0101-based triple combination therapy in advanced human papillomavirus (HPV)-positive cancers were recently announced. The triple combination of PDS0101—a novel T-cell HPV-specific immunotherapy—with the tumor-targeting IL-12...
Interim Analysis of Overall Survival in the monarchE Trial
As reported in The Lancet Oncology by Stephen R.D. Johnston, MD, PhD, and colleagues, an interim analysis of overall survival in the phase III monarchE trial has shown no significant benefit with the addition of adjuvant abemaciclib to endocrine therapy in patients with hormone receptor–positive,...
MonarchE Update: Benefit of Abemaciclib Increases Over Time
Results of a planned interim overall survival analysis of the phase III monarchE trial offer further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk breast cancer, according to Stephen R.D....
Adding Capivasertib to Fulvestrant May Improve Progression-Free Survival in Patients With Advanced Hormone Receptor–Positive Breast Cancer
In patients with hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitors, the addition of the investigational AKT inhibitor capivasertib to fulvestrant doubled the median progression-free survival compared with placebo plus fulvestrant, according to results...
Expert Point of View: Sanjay Popat, FRCP, PhD
“Adjuvant osimertinib has been adopted widespread as a standard of care as a result of the primary results of ADAURA,” said formal discussant Sanjay Popat, FRCP, PhD, medical oncologist and lung specialist at the Royal Marsden Hospital, NHS Foundation Trust, London. “We have more granularity about ...
